Webpharma SPT AS
ASActiveOrg 981578880Karoline Kristiansens Vei 5, 0661 OsloWholesale of pharmaceutical and medical goods· NACE 4646Est. 1999 · 26 years old13 employees
Loading company…
Overview
Webpharma SPT AS is a Norwegian AS based in Oslo, operating in the Wholesale of pharmaceutical and medical goods sector. Incorporated in 1999, the company has 13 employees and reported revenue of NOK 157.8m in its latest annual filing.
Revenue 2025
157.8M NOK
+9% vs 2024
EBITDA margin
1.2 %
+157% vs 2024
Net profit 2025
0.6M NOK
+235% vs 2024
Key ratios
See full ratios →Solidity ratioEquity ÷ Total assets × 100
6.7 %
WeakAmong the 30% lowest rated companies in the industry
20212025
Liquidity ratioCurrent assets ÷ Short-term debt
1.0×
WeakAmong the 30% lowest rated companies in the industry
20212025
Return on assets (ROA)Net profit ÷ Total assets × 100
1.6 %
AverageAround the average of companies in the same industry
20212025
EBITDA — year on year
NOK thousandsKey figures
Annual report 2025| Revenue | 157.8M NOK | +9% |
| EBITDA | 1.9M NOK | +157% |
| Net profit | 0.6M NOK | +235% |
| Total assets | 38.1M NOK | +48% |
| Equity | 2.6M NOK | +32% |
| Employees | 13 | — |
Company information
Legal name
WEBPHARMA SPT AS
Org number
981578880
Legal form
Aksjeselskap
NACE code
Founded
22 December 1999 · 26 years
Share capital
NOK 1,188,264
Employees
13 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap.
Company purpose
Utvikle innovative systemløsninger innen områdene teknologi, internett baserte tjenester og system for elektronisk handel. Selskapet skal kunne levere en eller flere produktløsninger. Selskapet skal kunne lisensiere ut systemløsninger, og rettighetsbeskytte de varemerker og produkter som selskapet utvikler. Selskapet vil kunne inneha produktrettigheter, utvikle egne legemidler, drive import og eksport av legemidler, utvikle systemer for bedriftshelsetjeneste, samt å kunne investere i annen virksomhet, og hva hermed står i forbindelse innen investering og utvikling av selskaper.
(no translation available)
Address
Karoline Kristiansens Vei 5, 0661 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Financial development
In its most recent annual report (2025), Webpharma SPT AS reported revenue of NOK 157.8m, an increase of 9% on the year before. The figures on this page draw on 5 annual filings covering 2021 to 2025. The bottom line showed a net profit of NOK 624.0k, and the EBITDA margin stood at 1.2%.
At the end of 2025, equity financed 6.7% of the balance sheet, and current assets covered short-term debt 1 times.
Financials
Revenue
NOK millionsEBITDA
NOK thousandsIncome statement
NOK thousands| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 157,755 | 144,300 | 125,942 | 114,816 | 111,497 |
| Staff expenses | -7,324 | -6,725 | -6,498 | -5,698 | -6,327 |
| EBITDA | 1,939 | 755 | 1,458 | 866 | 2,532 |
| Depreciation & amort. | -1,262 | -1,139 | -1,159 | -1,702 | -2,074 |
| EBIT | 678 | -384 | 299 | -836 | 457 |
| Net financials | -54 | -78 | -120 | -29 | -10 |
| Profit before tax | 624 | -462 | 179 | -865 | 447 |
| Tax | -0 | -0 | -0 | -0 | -0 |
| Net profit | 624 | -462 | 179 | -865 | 447 |
Get a credit rating – not just the numbers
Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.
Balance sheet
NOK thousands| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | 38,146 | 25,707 | 25,535 | 26,449 | 25,897 |
| Equity | 2,554 | 1,930 | 2,392 | 2,213 | 3,078 |
| Long-term debt | 5 | 5 | 5 | 5 | 5 |
| Short-term debt | 35,586 | 23,772 | 23,138 | 24,230 | 22,814 |
| Total debt | 35,591 | 23,777 | 23,143 | 24,235 | 22,819 |
Financial ratios
5-year trendEBITDA margin
1.2 %
20212025
Equity ratio
6.7 %
WeakAmong the 30% lowest rated companies in the industry
20212025
Return on equity
24.4 %
StrongAmong the 40% highest rated companies in the industry
20212025
Net profit margin
0.4 %
WeakAmong the 40% lowest rated companies in the industry
20212025
Asset turnover
4.14×
Very strongAmong the 20% highest rated companies in the industry
20212025
Debt / equity
13.93×
Very weakAmong the 10% lowest rated companies in the industry
20212025
Sector performance
28 of 28 ratios graded28 financial ratios from the latest filing, each graded against companies in the same industry.
Profitability
Gross marginVery weak
Among the 20% lowest rated companies in the industry
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
Operating marginWeak
Among the 40% lowest rated companies in the industry
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
Net profit marginWeak
Among the 40% lowest rated companies in the industry
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Return on equity (ROE)Strong
Among the 40% highest rated companies in the industry
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Return on assets (ROA)Average
Around the average of companies in the same industry
Net profit as a percentage of total assets — the return generated on the capital employed.
Return on net assets (RONA)Strong
Among the 40% highest rated companies in the industry
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Basic earning power (BEP)Average
Around the average of companies in the same industry
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Capacity ratioAverage
Around the average of companies in the same industry
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
Liquidity
Current ratioWeak
Among the 30% lowest rated companies in the industry
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Quick ratioWeak
Among the 40% lowest rated companies in the industry
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Cash ratioVery weak
Among the 20% lowest rated companies in the industry
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Current assets to equityVery weak
Among the 10% lowest rated companies in the industry
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Fixed assets to long-term capitalVery weak
Among the 20% lowest rated companies in the industry
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Cash conversion ratioVery strong
Among the 10% highest rated companies in the industry
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Debt & solvency
Solidity ratioWeak
Among the 30% lowest rated companies in the industry
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Debt ratioWeak
Among the 30% lowest rated companies in the industry
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Debt to equityVery weak
Among the 10% lowest rated companies in the industry
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Liabilities to equityVery weak
Among the 10% lowest rated companies in the industry
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Income to debtAverage
Around the average of companies in the same industry
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA to debtAverage
Around the average of companies in the same industry
EBITDA relative to debt — how much operating earnings are available to service the debt.
Interest coverageAverage
Around the average of companies in the same industry
The ability to pay the interest on the company's debt out of its earnings.
Interest rate on debtAverage
Around the average of companies in the same industry
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
Interest marginAverage
Around the average of companies in the same industry
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Efficiency & development
Asset turnoverVery strong
Among the 20% highest rated companies in the industry
Revenue relative to total assets — the ability to generate revenue from the asset base.
Inventory turnoverWeak
Among the 30% lowest rated companies in the industry
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
Equity to contributed capitalAverage
Around the average of companies in the same industry
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
One-year change in equityVery strong
Among the 20% highest rated companies in the industry
The size of this year's increase or decrease in the company's equity.
One-year change in debtVery weak
Among the 20% lowest rated companies in the industry
The size of this year's increase or decrease in the company's debt.
Annual reports & filings
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
People & ownership
Management
Actively employed in the business| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
AA Deputy Member | Deputy Member | 2025 |
JD Chief Executive Officer | Chief Executive Officer | 2007 |
HR Deputy Member | Deputy Member | 2025 |
Board of directors
Non-executive oversight| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
JD Chairman | Chairman | 2021 |
RI Board of Directors | Board of Directors | 2021 |
Former (2)
AA Board of Directors | Board of Directors | 2021 – 2025 |
HR Board of Directors | Board of Directors | 2021 – 2025 |
Shareholders
Active legal owners| Shareholder | Type | Ownership | Votes | Registered |
|---|---|---|---|---|
| Company | 47.88% | 47.88% | 2020 | |
| Company | 30.03% | 30.03% | 2020 | |
| Company | 5.99% | 5.99% | 2020 | |
| Company | 4.49% | 4.49% | 2020 | |
| Individual | 2.37% | 2.37% | 2023 | |
| Individual | 2.37% | 2.37% | 2020 | |
| Company | 1.63% | 1.63% | 2020 | |
| Individual | 1.12% | 1.12% | 2020 | |
| Individual | 2.37% | 2.37% | 2020 |
One in three Danish companies experiences fraud
Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.
Related companies
Company hierarchy
As Selvaag Invest30.0343%Sesam Invest As47.8769%Altea As5.9899%Vefring Invest As4.49%Ulle Holding As1.63%
Webpharma SPT AS (this company)Board network connections
Board members of Webpharma SPT AS also hold positions in 55 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Arnljot August Marconini Alfsen | Deputy Member | 28 companiesMany roles |
| Rune Ingve Fløgstad | Board of Directors | 22 companiesMany roles |
| Hans Ragnar Preus | Deputy Member | 3 companies |
| Jan-Henrik Døhlen | Chief Executive Officer | 2 companies |
Frequently asked questions
What is the Org number of Webpharma SPT AS?
Webpharma SPT AS is registered with Brønnøysundsregistrene under Org 981578880.
What is the revenue of Webpharma SPT AS?
Webpharma SPT AS reported revenue of NOK 157.8m in 2025.
How many employees does Webpharma SPT AS have?
Webpharma SPT AS employs 13 people as of the latest annual report.
Who is the CEO of Webpharma SPT AS?
Jan-Henrik Døhlen is the CEO of Webpharma SPT AS, in role since 2007.
Who is the chairman of Webpharma SPT AS?
Jan-Henrik Døhlen chairs the board of Webpharma SPT AS, in role since 2021.
Where is Webpharma SPT AS headquartered?
Webpharma SPT AS's registered address is Karoline Kristiansens Vei 5.